CTLA-4 inhibition facilitates follicular T and B cell interaction and the production of tumor-specific antibodies

Int J Cancer. 2023 May 1;152(9):1964-1976. doi: 10.1002/ijc.34438. Epub 2023 Jan 27.

Abstract

Immune checkpoint inhibitors (ICIs) induce activation and expansion of cytotoxic T cells. To depict a comprehensive immune cell landscape reshaped by the CTLA-4 checkpoint inhibitor, we performed single-cell RNA sequencing in a mouse syngeneic tumor transplant model. After CTLA-4 inhibition, tumor regression was accompanied by massive immune cell expansion, especially in T and B cells. We found that B cells in tumor transplant represented follicular, germinal center and plasma B cells, some of which shared identical B cell receptor clonotypes and possessed tumor reactivity. Furthermore, the posttreatment tumor contained a tertiary lymphoid-like structure with intermingled T and B cells. These data suggest germinal center formation within the tumor mass and in situ differentiation of tumor-specific plasma cells. Taken together, our data provide a panoramic view of the immune microenvironment after CTLA-4 inhibition and suggest a role for tumor-specific B cells in antitumor immunity.

Keywords: BCR sequencing; CTLA-4 inhibition; humoral antitumor immunity; mouse transplant model; single-cell RNA sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies*
  • B-Lymphocytes
  • CTLA-4 Antigen
  • Cell Communication
  • Mice
  • Neoplasms*
  • Tumor Microenvironment

Substances

  • CTLA-4 Antigen
  • Antibodies